EV/OHPC has been used in the treatment of threatened miscarriage (habitual abortion) and for other indications under the brand name Gravibinon among others in Europe and Latin America. The combination has also been used as a form of pseudopregnancy (high-dose estrogen/progestogen therapy), for instance to treat osteopenia due to hypogonadism, to induce feminization in hypogonadism/delayed puberty, and as a means of hormonal breast enhancement to produce breast enlargement. EV/OHPC is administered daily to once per week or less often for the treatment of threatened miscarriage, for use as a form of pseudopregnancy, and for other indications. EV/OHPC is used as a combined injectable contraceptive to prevent pregnancy in women under the brand name Injectable No. 1 (or Chinese Injectable No. 1) in China as well. When used as a combined injectable contraceptive, EV/OHPC is given twice in the first month and then once per month thereafter. Available forms EV/OHPC is available for general use (e.g., as Gravibinon) in the form of ampoules containing 5 to 10 mg estradiol valerate (EV) and 250 to 500 mg<unk>  caproate (OHPC). It is available for use as a combined injectable contraceptive specifically at a dose of 5 mg EV and 250 mg OHPC.
Estradiol valerate/hydroxyprogesterone caproate
Estradiol benzoate/hydroxyprogesterone caproate
Testosterone propionate/testosterone enanthate
Estradiol dipropionate/hydroxyprogesterone caproate
Estradiol valerate/testosterone enanthate
Estradiol benzoate/testosterone propionate
Estradiol cypionate/hydroxyprogesterone caproate
Estradiol benzoate/progesterone/testosterone propionate